An overview of chemotherapy for mesothelioma

被引：31

作者：

Krug, LM ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY 10021 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2005年 / 19卷 / 06期

关键词：

D O I：

10.1016/j.hoc.2005.09.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Mesothelioma is an extraordinarily challenging disease to treat. While numerous clinical trials testing various chemotherapeutic agents have been conducted over the last several decades, only recently have larger studies proven the efficacy of newer chemotherapy regimens. This article reviews the data regarding specific classes of chemotherapeutic agents. The role of treatment in various disease settings and the difficulty in assessing the benefit of that therapy is discussed. Finally, an update is provided on novel therapeutics being testing in mesothelioma.

引用

页码：1117 / +

页数：21

共 114 条

[1]

MALIGNANT PLEURAL MESOTHELIOMA - PHASE-II PILOT-STUDY OF IFOSFAMIDE AND MESNA [J].

ALBERTS, AS ;

FALKSON, G ;

VANZYL, L .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (09) :698-699

[2]

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma [J].

Andreopoulou, E ;

Ross, PJ ;

O'Brien, MER ;

Ford, HER ;

Priest, K ;

Eisen, T ;

Norton, A ;

Ashley, S ;

Smith, IE .

ANNALS OF ONCOLOGY, 2004, 15 (09) :1406-1412

[3]

ARDIZZONI A, 1991, CANCER, V67, P2984, DOI 10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO

[4]

2-Q

[5]

The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma:: an EORTC phase II study (08992) [J].

Baas, P ;

Ardizzoni, A ;

Grossi, F ;

Nackaerts, K ;

Numico, G ;

Van Marck, E ;

van de Vijver, M ;

Monetti, F ;

Smid-Geirnaerdt, MJA ;

van Zandwijk, N ;

Debruyne, C ;

Legrand, C ;

Giaccone, G .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) :353-357

[6]

Caelyx™ in malignant mesothelioma:: A phase II EORTC study [J].

Baas, P ;

van Meerbeeck, J ;

Groen, H ;

Schouwink, H ;

Burgers, S ;

Daamen, S ;

Giaccone, G .

ANNALS OF ONCOLOGY, 2000, 11 (06) :697-700

[7]

BAJORIN D, 1987, CANCER TREAT REP, V71, P857

[8]

Belani Chandra P, 2004, Clin Lung Cancer, V6, P43, DOI 10.3816/CLC.2004.n.020

[9]

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis [J].

Berghmans, T ;

Paesmans, M ;

Lalami, Y ;

Louviaux, I ;

Luce, S ;

Mascaux, C ;

Meert, AP ;

Sculier, JP .

LUNG CANCER, 2002, 38 (02) :111-121

[10]

BOUTIN C, 1987, CANCER TREAT REP, V71, P205

← 1 2 3 4 5 6 7 8 9 10 →